JP Morgan Upgrades GoodRx Holdings (GDRX)
Fintel reports that on March 1, 2024, JP Morgan upgraded their outlook for GoodRx Holdings (NasdaqGS:GDRX) from Neutral to Overweight .
Analyst Price Forecast Suggests 12.45% Downside
As of February 24, 2024, the average one-year price target for GoodRx Holdings is 7.31. The forecasts range from a low of 4.54 to a high of $12.60. The average price target represents a decrease of 12.45% from its latest reported closing price of 8.35.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for GoodRx Holdings is 912MM, an increase of 21.61%. The projected annual non-GAAP EPS is 0.35.
What is the Fund Sentiment?
There are 246 funds or institutions reporting positions in GoodRx Holdings. This is a decrease of 8 owner(s) or 3.15% in the last quarter. Average portfolio weight of all funds dedicated to GDRX is 0.32%, an increase of 14.25%. Total shares owned by institutions increased in the last three months by 4.06% to 146,400K shares. 
The put/call ratio of GDRX is 0.31, indicating a bullish outlook.
What are Other Shareholders Doing?
Francisco Partners Management holds 84,701K shares representing 20.86% ownership of the company. No change in the last quarter.
Ameriprise Financial holds 7,002K shares representing 1.72% ownership of the company. In it's prior filing, the firm reported owning 2,631K shares, representing an increase of 62.42%. The firm decreased its portfolio allocation in GDRX by 47.52% over the last quarter.
Rubric Capital Management holds 5,873K shares representing 1.45% ownership of the company.
Silver Lake Group, L.L.C. holds 3,532K shares representing 0.87% ownership of the company. No change in the last quarter.
Renaissance Technologies holds 2,977K shares representing 0.73% ownership of the company. In it's prior filing, the firm reported owning 2,738K shares, representing an increase of 8.02%. The firm increased its portfolio allocation in GDRX by 17.46% over the last quarter.
GoodRx Holdings Background Information
(This description is provided by the company.)
GoodRx Holdings, Inc. is a holding company that provides price comparison tool for prescriptions. The Company provides GoodRx platform, which aggregates and analyzes pricing data from a number of different sources. Its platform also provides access to medication savings programs, medical provider consultations and lab tests through its telehealth offerings, HeyDoctor and the GoodRx Telehealth Marketplace, and other healthcare related content. Its prescription offering provides price comparisons and negotiated prices on prescriptions. Its subscription offerings provide consumers and their families with access to lower prescription prices on select medications in select pharmacies for a monthly or annual subscription fee. Its pharmaceutical manufacturer solutions offering provides advertising and integrated consumer affordability solutions to pharmaceutical manufacturers.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.